Seventeen years since the first use of granulocyte-macrophage colony-stimulating factor (GM-CSF) tumour vaccine to unleash T-cell generation for anti-CTLA-4 blockade response in B16 melanomas [20, 21], extensive pre-clinical research has been carried out to improve DCs immunogenic functions. Here, CSF2 is linked to melanoma.